1
|
Maupetit-Mehouas S, Court F, Bourgne C, Guerci-Bresler A, Cony-Makhoul P, Johnson H, Etienne G, Rousselot P, Guyotat D, Janel A, Hermet E, Saugues S, Berger J, Arnaud P, Berger MG. DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34 + CD15 - cells in early chronic-phase chronic myeloid leukemia. Mol Oncol 2018; 12:814-829. [PMID: 29575763 PMCID: PMC5983208 DOI: 10.1002/1878-0261.12191] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2018] [Revised: 02/07/2018] [Accepted: 03/07/2018] [Indexed: 12/15/2022] Open
Abstract
Despite the high efficiency of tyrosine kinase inhibitors (TKI), some patients with chronic myeloid leukemia (CML) will display residual disease that can become resistant to treatment, indicating intraclonal heterogeneity in chronic‐phase CML (CP‐CML). To determine the basis of this heterogeneity, we conducted the first exhaustive characterization of the DNA methylation pattern of sorted CP‐CML CD34+CD15− (immature) and CD34−CD15+ (mature) cells at diagnosis (prior to any treatment) and compared it to that of CD34+CD15− and CD34−CD15+ cells isolated from healthy donors (HD). In both cell types, we identified several hundreds of differentially methylated regions (DMRs) showing DNA methylation changes between CP‐CML and HD samples, with only a subset of them in common between CD34+CD15− and CD34−CD15+ cells. This suggested DNA methylation variability within the same CML clone. We also identified 70 genes that could be aberrantly repressed upon hypermethylation and 171 genes that could be aberrantly expressed upon hypomethylation of some of these DMRs in CP‐CML cells, among which 18 and 81, respectively, were in CP‐CML CD34+CD15− cells only. We then validated the DNA methylation and expression defects of selected candidate genes. Specifically, we identified GAS2, a candidate oncogene, as a new example of gene the hypomethylation of which is associated with robust overexpression in CP‐CML cells. Altogether, we demonstrated that DNA methylation abnormalities exist at early stages of CML and can affect the transcriptional landscape of malignant cells. These observations could lead to the development of combination treatments with epigenetic drugs and TKI for CP‐CML.
Collapse
Affiliation(s)
- Stéphanie Maupetit-Mehouas
- GReD, Université Clermont Auvergne, CNRS, INSERM, Clermont-Ferrand, France.,Hématologie Biologique, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France
| | - Franck Court
- GReD, Université Clermont Auvergne, CNRS, INSERM, Clermont-Ferrand, France
| | - Céline Bourgne
- Hématologie Biologique, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France.,Equipe d'Accueil 7453 CHELTER, Université Clermont Auvergne, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France
| | - Agnès Guerci-Bresler
- Hématologie Clinique, CHRU Nancy, Hôpitaux de Brabois, Vandoeuvre-lès-Nancy, France
| | | | - Hyacinthe Johnson
- Institut d'Hématologie de Basse Normandie, CHU de Caen, Caen Cedex 9, France
| | - Gabriel Etienne
- Hématologie Clinique, Institut Bergonié, Bordeaux Cedex, France
| | - Philippe Rousselot
- Centre Hospitalier de Versailles, service d'Hématologie et d'Oncologie, Le Chesney, France
| | - Denis Guyotat
- Département d'Hématologie, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France
| | - Alexandre Janel
- Hématologie Biologique, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France.,Equipe d'Accueil 7453 CHELTER, Université Clermont Auvergne, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France
| | - Eric Hermet
- Hématologie Clinique Adulte, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France
| | - Sandrine Saugues
- Hématologie Biologique, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France.,CRB-Auvergne, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France
| | - Juliette Berger
- Hématologie Biologique, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France.,Equipe d'Accueil 7453 CHELTER, Université Clermont Auvergne, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France.,CRB-Auvergne, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France
| | - Philippe Arnaud
- GReD, Université Clermont Auvergne, CNRS, INSERM, Clermont-Ferrand, France
| | - Marc G Berger
- Hématologie Biologique, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France.,Equipe d'Accueil 7453 CHELTER, Université Clermont Auvergne, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France.,CRB-Auvergne, CHU Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand Cedex 1, France
| |
Collapse
|
2
|
Janel A, Berger J, Bourgne C, Lemal R, Boiret-Dupré N, Dubois-Galopin F, Déchelotte P, Bothorel C, Hermet E, Chabi S, Bay JO, Lambert C, Pereira B, Pflumio F, Haddad R, Berger MG. Bone marrow hematons: An access point to the human hematopoietic niche. Am J Hematol 2017. [PMID: 28639326 DOI: 10.1002/ajh.24830] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
To understand the complex interactions between hematopoietic stem cells and the bone marrow niche, a human experimental model is needed. Our hypothesis is that hematons are an appropriate ex vivo model of human bone marrow. We analyzed the hierarchical hematopoietic cell content and the tissue organization of single hematons from healthy donors. Most (>90%) hematons contained precursors of all cell lineages, myeloid progenitors, and LTC-ICs without preferential commitment. Approximately, half of the hematons could generate significant levels of lympho-myeloid hematopoiesis after transplantation in an NSG mouse model, despite the low absolute numbers of transplanted CD34+ cells. Mesenchymal STRO-1+ and/or CD271+ cells formed a critical network that preserved hematon cohesion, and STRO-1+ cells colocalized with most hematopoietic CD34+ cells (68%). We observed an influence of age and gender. These structures represent a particularly attractive model for studying the homeostasis of the bone marrow niche and pathological changes that occur during diseases.
Collapse
Affiliation(s)
- Alexandre Janel
- CHU Clermont-Ferrand, Hôpital Estaing, Hématologie Biologique; 1 place Lucie et Raymond Aubrac, Clermont-Ferrand Cedex 1 63003 France
- Université Clermont Auvergne, Equipe d'accueil l'EA 7453 CHELTER; 1 place L. et R. Aubrac, Clermont-Ferrand Cedex 63003 France
| | - Juliette Berger
- CHU Clermont-Ferrand, Hôpital Estaing, Hématologie Biologique; 1 place Lucie et Raymond Aubrac, Clermont-Ferrand Cedex 1 63003 France
- Université Clermont Auvergne, Equipe d'accueil l'EA 7453 CHELTER; 1 place L. et R. Aubrac, Clermont-Ferrand Cedex 63003 France
- CHU Clermont-Ferrand, Hôpital Estaing, CRB-Auvergne; 1 place Lucie et Raymond Aubrac, Clermont-Ferrand Cedex 1 63003 France
| | - Céline Bourgne
- CHU Clermont-Ferrand, Hôpital Estaing, Hématologie Biologique; 1 place Lucie et Raymond Aubrac, Clermont-Ferrand Cedex 1 63003 France
- Université Clermont Auvergne, Equipe d'accueil l'EA 7453 CHELTER; 1 place L. et R. Aubrac, Clermont-Ferrand Cedex 63003 France
| | - Richard Lemal
- Université Clermont Auvergne, Equipe d'accueil l'EA 7453 CHELTER; 1 place L. et R. Aubrac, Clermont-Ferrand Cedex 63003 France
- CHU Clermont-Ferrand, Hôpital Estaing, Hématologie Clinique; 1 place Lucie et Raymond Aubrac, Clermont-Ferrand Cedex 1 63003 France
| | - Nathalie Boiret-Dupré
- CHU Clermont-Ferrand, Hôpital Estaing, Hématologie Biologique; 1 place Lucie et Raymond Aubrac, Clermont-Ferrand Cedex 1 63003 France
| | - Frédérique Dubois-Galopin
- CHU de Toulouse, Hôpital Purpan, Laboratoire d'Hématologie, Place du Docteur Baylac - TSA 40031 31059; Toulouse Cedex 9 France
| | - Pierre Déchelotte
- CHU Clermont-Ferrand, Hôpital Estaing, Anatomie Pathologique; 1 place Lucie et Raymond Aubrac, Clermont-Ferrand Cedex 1 63003 France
| | - Charlotte Bothorel
- CHU Clermont-Ferrand, Hôpital Estaing, Anatomie Pathologique; 1 place Lucie et Raymond Aubrac, Clermont-Ferrand Cedex 1 63003 France
| | - Eric Hermet
- CHU Clermont-Ferrand, Hôpital Estaing, Hématologie Clinique; 1 place Lucie et Raymond Aubrac, Clermont-Ferrand Cedex 1 63003 France
| | - Sara Chabi
- INSERM UMR967, CEA/DSV/iRCM, Laboratory of Hematopoietic Stem cells and Leukemic Cells, Equipe labellisée par la Ligue Nationale Contre le Cancer, Université Paris Diderot, Université Paris-Saclay, Univ Paris Sud, Commissariat à l'Energie Atomique et aux Energies Alternatives; Fontenay-aux-Roses 92265 France
| | - Jacques-Olivier Bay
- Université Clermont Auvergne, Equipe d'accueil l'EA 7453 CHELTER; 1 place L. et R. Aubrac, Clermont-Ferrand Cedex 63003 France
- CHU Clermont-Ferrand, Hôpital Estaing, Hématologie Clinique; 1 place Lucie et Raymond Aubrac, Clermont-Ferrand Cedex 1 63003 France
| | - Céline Lambert
- CHU Clermont-Ferrand, Département de Recherche Clinique et Innovation, Bd Léon Malfreyt; Clermont-Ferrand France
| | - Bruno Pereira
- CHU Clermont-Ferrand, Département de Recherche Clinique et Innovation, Bd Léon Malfreyt; Clermont-Ferrand France
| | - Françoise Pflumio
- CHU Clermont-Ferrand, Hôpital Estaing, Anatomie Pathologique; 1 place Lucie et Raymond Aubrac, Clermont-Ferrand Cedex 1 63003 France
| | - Rima Haddad
- CHU Clermont-Ferrand, Hôpital Estaing, Anatomie Pathologique; 1 place Lucie et Raymond Aubrac, Clermont-Ferrand Cedex 1 63003 France
| | - Marc G. Berger
- CHU Clermont-Ferrand, Hôpital Estaing, Hématologie Biologique; 1 place Lucie et Raymond Aubrac, Clermont-Ferrand Cedex 1 63003 France
- Université Clermont Auvergne, Equipe d'accueil l'EA 7453 CHELTER; 1 place L. et R. Aubrac, Clermont-Ferrand Cedex 63003 France
- CHU Clermont-Ferrand, Hôpital Estaing, CRB-Auvergne; 1 place Lucie et Raymond Aubrac, Clermont-Ferrand Cedex 1 63003 France
- CHU Clermont-Ferrand, Hôpital Estaing, Hématologie Clinique; 1 place Lucie et Raymond Aubrac, Clermont-Ferrand Cedex 1 63003 France
| |
Collapse
|
3
|
Janel A, Dubois-Galopin F, Bourgne C, Berger J, Tarte K, Boiret-Dupré N, Boisgard S, Verrelle P, Déchelotte P, Tournilhac O, Berger MG. The Chronic Lymphocytic Leukemia Clone Disrupts the Bone Marrow Microenvironment. Stem Cells Dev 2014; 23:2972-82. [DOI: 10.1089/scd.2014.0229] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Affiliation(s)
- Alexandre Janel
- Hématologie Biologique, CHU (University Hospital Center) Clermont-Fd, Hopital Estaing, Clermont-Ferrand, France
- EA7283 CREaT, Clermont Université, Université d'Auvergne, Clermont-Ferrand, France
| | | | - Céline Bourgne
- Hématologie Biologique, CHU (University Hospital Center) Clermont-Fd, Hopital Estaing, Clermont-Ferrand, France
| | - Juliette Berger
- Hématologie Biologique, CHU (University Hospital Center) Clermont-Fd, Hopital Estaing, Clermont-Ferrand, France
| | - Karin Tarte
- INSERM U917–MICA, University of Medicine, Rennes, France
| | - Nathalie Boiret-Dupré
- Hématologie Biologique, CHU (University Hospital Center) Clermont-Fd, Hopital Estaing, Clermont-Ferrand, France
- EA7283 CREaT, Clermont Université, Université d'Auvergne, Clermont-Ferrand, France
| | - Stéphane Boisgard
- Orthopédie Traumatologie, CHU (University Hospital Center) Clermont-Fd, Hospital Montpied, Clermont-Ferrand, France
| | - Pierre Verrelle
- EA7283 CREaT, Clermont Université, Université d'Auvergne, Clermont-Ferrand, France
| | - Pierre Déchelotte
- Anatomie Pathologique, CHU Clermont-Fd, Hopital Estaing, Clermont-Ferrand, France
| | - Olivier Tournilhac
- EA7283 CREaT, Clermont Université, Université d'Auvergne, Clermont-Ferrand, France
- Hématologie Clinique Adulte, CHU Clermont-Fd, Hopital Estaing, Clermont-Ferrand, France
| | - Marc G. Berger
- Hématologie Biologique, CHU (University Hospital Center) Clermont-Fd, Hopital Estaing, Clermont-Ferrand, France
- EA7283 CREaT, Clermont Université, Université d'Auvergne, Clermont-Ferrand, France
- Hématologie Clinique Adulte, CHU Clermont-Fd, Hopital Estaing, Clermont-Ferrand, France
| |
Collapse
|
4
|
Bourgne C, Janel A, Berger J, Rapatel C, Tournilhac O, Hermet E, Guerci A, Lioret F, Briançon A, Bamdad M, Boiret-Dupré N, Berger MG. Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk³⁴⁸) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML). Leuk Res 2014; 39:329-34. [PMID: 25612940 DOI: 10.1016/j.leukres.2014.11.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2014] [Revised: 11/19/2014] [Accepted: 11/22/2014] [Indexed: 11/27/2022]
Abstract
We investigated Syk as a potential marker of CML progression. We observed a significant over-expression of Syk mRNA and constitutive phosphorylation of Syk Y348 in blast cells from six AP or BP-CML, but not in 15 CML in chronic phase. We could follow in vivo the recurrence of pSyk(348) throughout blast cell escape, despite observing storage of dasatinib in blast cells. A combination of dasatinib and R406 did not improve therapeutic efficacy in vitro. Our results strongly suggest that Syk activation could be a relevant biomarker of disease progression and dasatinib resistance but is probably not a molecular target.
Collapse
Affiliation(s)
- Céline Bourgne
- Hématologie Biologique, CHU Estaing, 1 Place Lucie Aubrac, 63003 Clermont-Ferrand Cedex 1, France
| | - Alexandre Janel
- Hématologie Biologique, CHU Estaing, 1 Place Lucie Aubrac, 63003 Clermont-Ferrand Cedex 1, France
| | - Juliette Berger
- Hématologie Biologique, CHU Estaing, 1 Place Lucie Aubrac, 63003 Clermont-Ferrand Cedex 1, France
| | - Chantal Rapatel
- Hématologie Biologique, CHU Estaing, 1 Place Lucie Aubrac, 63003 Clermont-Ferrand Cedex 1, France
| | - Olivier Tournilhac
- Hématologie Clinique, CHU Estaing, 1 Place Lucie Aubrac, 63003 Clermont-Ferrand Cedex 1, France
| | - Eric Hermet
- Hématologie Clinique, CHU Estaing, 1 Place Lucie Aubrac, 63003 Clermont-Ferrand Cedex 1, France
| | - Agnès Guerci
- Hématologie et Médecine Interne, CHU Brabois, Rue Morvan, 54500 Vandoeuvre-lès-Nancy, France
| | - Frédérique Lioret
- Hématologie Biologique, CHU Estaing, 1 Place Lucie Aubrac, 63003 Clermont-Ferrand Cedex 1, France
| | - Aurélie Briançon
- Hématologie Biologique, CHU Estaing, 1 Place Lucie Aubrac, 63003 Clermont-Ferrand Cedex 1, France
| | - Mahchid Bamdad
- Laboratoire Microorganismes, Génome et Environnement (LMGE) - UMR CNRS 6023, Université Blaise Pascal, UFR Sciences et Technologies, 24, avenue des Landais, BP 80026, 63171 Aubière Cedex, France
| | - Nathalie Boiret-Dupré
- Hématologie Biologique, CHU Estaing, 1 Place Lucie Aubrac, 63003 Clermont-Ferrand Cedex 1, France
| | - Marc G Berger
- Hématologie Biologique, CHU Estaing, 1 Place Lucie Aubrac, 63003 Clermont-Ferrand Cedex 1, France.
| |
Collapse
|
5
|
Janel A, Roszyk L, Rapatel C, Mareynat G, Berger MG, Serre‐Sapin A. Proposal of a score combining red blood cell indices for early differentiation of beta‐thalassemia minor from iron deficiency anemia. Hematology 2013; 16:123-7. [DOI: 10.1179/102453311x12940641877849] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Affiliation(s)
- Alexandre Janel
- Hématologie Biologique/ImmunologieCHU, Hôtel Dieu, Boulevard Léon Malfreyt, Clermont Ferrand, France
| | - Laurence Roszyk
- Biochimie MédicaleCHU, Hôtel Dieu, Boulevard Léon Malfreyt, Clermont Ferrand, France
| | - Chantal Rapatel
- Hématologie Biologique/ImmunologieCHU, Hôtel Dieu, Boulevard Léon Malfreyt, Clermont Ferrand, France
| | - Gabrielle Mareynat
- Hématologie Biologique/ImmunologieCHU, Hôtel Dieu, Boulevard Léon Malfreyt, Clermont Ferrand, France
| | - Marc G Berger
- Hématologie Biologique/ImmunologieCHU, Hôtel Dieu, Boulevard Léon Malfreyt, Clermont Ferrand, France
| | | |
Collapse
|
6
|
Bourgne C, Bamdad M, Janel A, Libert F, Gagnieu MC, Rapatel C, Pigeon P, Pereira S, Hermet E, Guerci A, Pereira B, Makhoul PC, Ansah AJ, Cahn JY, Guyotat D, Trouillier S, Berger J, Boiret-Dupré N, Berger MG. Measurement of imatinib uptake by flow cytometry. Cytometry A 2012; 81:996-1004. [DOI: 10.1002/cyto.a.22118] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2011] [Accepted: 07/17/2012] [Indexed: 12/22/2022]
|
7
|
Frédérique DG, Janel A, Veyrat-Masson R, Tournilhac O, Boiret-Dupré N, Coudoré MA, Rapatel C, Chassagne J, Tarte K, Berger M. 92: Bone Marrow Mesenchymal Stem Cells are altered in CLL. Bull Cancer 2010. [DOI: 10.1016/s0007-4551(15)31185-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|